Financial reports
10-K
2023 FY
Annual report
18 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
19 Apr 23
10-K/A
2022 FY
Annual report (amended)
10 Apr 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
Current reports
8-K
Abeona Therapeutics Provides Regulatory Update on Pz-cel
22 Apr 24
8-K
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
18 Mar 24
8-K
Abeona Therapeutics Announces $50 Million Credit Facility
8 Jan 24
8-K
Other Events
27 Nov 23
8-K
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
13 Nov 23
8-K
Changes in Registrant's Certifying Accountant
18 Oct 23
8-K
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
8 Aug 23
8-K
Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
7 Jul 23
8-K
Abeona Therapeutics Announces $25 Million Registered Direct Offering
3 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
17 May 23
Registration and prospectus
S-8
Registration of securities for employees
10 Oct 23
424B5
Prospectus supplement for primary offering
3 Jul 23
424B5
Prospectus supplement for primary offering
7 Jun 23
S-8
Registration of securities for employees
19 May 23
424B5
Prospectus supplement for primary offering
29 Mar 23
S-8
Registration of securities for employees
22 Mar 23
S-3
Shelf registration
30 Nov 22
424B5
Prospectus supplement for primary offering
12 Oct 22
S-8
Registration of securities for employees
31 Aug 22
424B5
Prospectus supplement for primary offering
19 Jul 22
Proxies
DEF 14A
Definitive proxy
19 Mar 24
DEF 14A
Definitive proxy
13 Apr 23
DEFA14A
Additional proxy soliciting materials
4 Aug 22
DEF 14A
Definitive proxy
11 Jul 22
DEF 14A
Definitive proxy
12 May 22
PRE 14A
Preliminary proxy
2 May 22
DEFA14A
Additional proxy soliciting materials
12 May 21
DEFR14A
Revised proxy
19 Apr 21
DEF 14A
Definitive proxy
9 Apr 21
PRE 14A
Preliminary proxy
30 Mar 21
Other
EFFECT
Notice of effectiveness
13 Dec 22
CORRESP
Correspondence with SEC
6 Dec 22
UPLOAD
Letter from SEC
5 Dec 22
EFFECT
Notice of effectiveness
25 Oct 21
CORRESP
Correspondence with SEC
19 Oct 21
CORRESP
Correspondence with SEC
30 Aug 21
CORRESP
Correspondence with SEC
27 Aug 21
UPLOAD
Letter from SEC
11 Jun 21
SEC STAFF
SEC staff action: Order
6 Mar 20
SEC STAFF
SEC staff action: Order
18 Feb 20
Ownership
4
Joseph Walter Vazzano
15 Mar 24
4
Brendan M. O'Malley
12 Mar 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Flynn James E
12 Feb 24
4
Vishwas Seshadri
7 Feb 24
4
Mark Alvino
22 Jan 24
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
10 Jan 24